Evidence map›Paper›PMID 23508471›Full record

ArticleFrontiers in immunology2013

Role of inositol phospholipid signaling in natural killer cell biology.

Matthew Gumbleton, William G Kerr

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Systematic Multiomic Analysis ofJournal of clinical medicine · 2020
    Article
  7. Review
  8. Myo-inositol in autoimmune thyroiditis, and hypothyroidism.Reviews in endocrine & metabolic disorders · 2018
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. PTEN is a negative regulator of NK cell cytolytic function.Journal of immunology (Baltimore, Md. : 1950) · 2015
    Article
  14. Effector Vγ9Vδ2 T cells dominate the human fetal γδ T-cell repertoire.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Matthew GumbletonDepartment of Microbiology and Immunology, State University of New York Upstate Medical University Syracuse, NY, USA.
William G Kerr
SUNY Upstate Medical University · USSyracuse University · US

Funding

Role of SHIP in NK Cell BiologyR01HL072523 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI KERR, WILLIAM GARROW · 2002 to 2014
$4.3M
Chemical Inhibition of SHIP1 To Facilitate Allogeneic Bone Marrow TransplantationR01HL107127 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI KERR, WILLIAM GARROW · 2011 to 2014
$1.6M
SHIP and Immunoregulatory Cell FunctionR01HL085580 · NHLBI · UPSTATE MEDICAL UNIVERSITY · PI KERR, WILLIAM GARROW · 2008 to 2011
$1.5M
NHLBI NIH HHS R01 HL072523NHLBI NIH HHS R01 HL085580NHLBI NIH HHS R01 HL107127
6 · The paper itself

Abstract

Natural killer (NK) cells are important for host defense against malignancy and infection. At a cellular level NK cells are activated when signals from activating receptors exceed signaling from inhibitory receptors. At a molecular level NK cells undergo an education process to both prevent autoimmunity and acquire lytic capacity. Mouse models have shown important roles for inositol phospholipid signaling in lymphocytes. NK cells from mice with deletion in different members of the inositol phospholipid signaling pathway exhibit defects in development, NK cell repertoire expression and effector function. Here we review the current state of knowledge concerning the function of inositol phospholipid signaling components in NK cell biology.

Indexed as

IFNγinositol phospholipidINPP4natural killer cellsPI3KPIP5KPTENSHIP

Identifiers

PMID23508471
PMCPMC3589743
OpenAlexW2102471023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.